RESUMO
PURPOSE: Ablative techniques have emerged as new potential therapeutic options for patients with locally advanced pancreatic cancer (LAPC). We explored the safety and feasibility of using TRANBERG|Thermal Therapy System (Clinical Laserthermia Systems AB, Lund, Sweden) in feedback mode for immunostimulating Interstitial Laser Thermotherapy (imILT) protocol, the newest ablative technique introduced for the treatment of LAPC. METHODS: The safety and feasibility results after the use of imILT protocol treatment in 15 patients of a prospective series of postsystemic therapy LAPC in two high-volume European institutions, the General and Pancreatic Unit of the Pancreas Institute, of the University of Verona, Italy, and the Department of Surgical Oncology of the Institut Paoli-Calmettes of Marseille, France, were assessed. RESULTS: The mean age was 66 ± 5 years, with a mean tumor size of 34.6 (±8) mm. The median number of cycles of pre-imILT chemotherapy was 6 (6-12). The procedure was performed in 13 of 15 (86.6%) cases; indeed, in two cases, the procedure was not performed; in one, the procedure was considered technically demanding; in the other, liver metastases were found intraoperatively. In all treated cases, the procedure was completed. Three late pancreatic fistulas developed over four overall adverse events (26.6%) and were attributed to imILT. Mortality was nil. A learning curve is necessary to interpret and manage the laser parameters. CONCLUSIONS: Safety, feasibility, and device handling outcomes of using TRANBERG|Thermal Therapy System with temperature probes in feedback mode and imILT protocol on LAPC were not satisfactory. The metastatic setting may be appropriate to evaluate the hypothetic abscopal effect.#NCT02702986 and #NCT02973217.
Assuntos
Hipertermia Induzida/efeitos adversos , Imunoterapia/efeitos adversos , Terapia a Laser/efeitos adversos , Fístula Pancreática/epidemiologia , Neoplasias Pancreáticas/terapia , Idoso , Ensaios Clínicos Fase II como Assunto , Estudos de Viabilidade , Feminino , França , Humanos , Hipertermia Induzida/instrumentação , Hipertermia Induzida/métodos , Imunoterapia/instrumentação , Imunoterapia/métodos , Itália , Terapia a Laser/instrumentação , Terapia a Laser/métodos , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Pâncreas/imunologia , Pâncreas/patologia , Pâncreas/efeitos da radiação , Pâncreas/cirurgia , Fístula Pancreática/etiologia , Fístula Pancreática/patologia , Neoplasias Pancreáticas/imunologia , Neoplasias Pancreáticas/patologia , Estudos Prospectivos , Resultado do TratamentoRESUMO
Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy for cancers that uses NIR light and antibody-photosensitizer (IR700) conjugates. However, it is difficult to deliver NIR light into the bile duct for cholangiocarcinoma (CCA) from the conventional extracorporeal apparatus. Thus, in this study, we developed a dedicated catheter with light emitting diodes (LEDs) that supersedes conventional external irradiation devices; we investigated the therapeutic effect of NIR-PIT for CCA using the novel catheter. The new catheter was designed to be placed in the bile duct and a temperature sensor was attached to the tip of the catheter to avoid thermal burn. An anti-epidermal growth factor receptor (EGFR) antibody, Panitumumab-IR700 conjugate or anti-human epidermal growth factor receptor type 2 (HER2) antibody, Trastuzumab-IR700 conjugate, was used with EGFR- or HER2-expressing cell lines, respectively. The in vitro efficacy of NIR-PIT was confirmed in cultured cells; the capability of the new catheter for NIR-PIT was then tested in a mouse tumor model. NIR-PIT via the developed catheter treated CCA xenografts in mice. NIR-PIT had an effect in Panitumumab-IR700 conjugate- and Trastuzumab-IR700 conjugate-treated CCA cells that depended on the receptor expression level. Tumor growth was significantly suppressed in mice treated with NIR-PIT using the novel catheter compared with controls (P < .01). NIR-PIT was an effective treatment for EGFR- and HER2-expressing CCA cells, and the novel catheter with mounted LEDs was useful for NIR-PIT of CCA.
Assuntos
Neoplasias dos Ductos Biliares/terapia , Colangiocarcinoma/terapia , Imunoterapia/instrumentação , Terapia com Luz de Baixa Intensidade/instrumentação , Animais , Catéteres , Linhagem Celular Tumoral , Feminino , Humanos , Imunoterapia/métodos , Raios Infravermelhos/uso terapêutico , Terapia com Luz de Baixa Intensidade/métodos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Panitumumabe/farmacologia , Fármacos Fotossensibilizantes/farmacologia , Trastuzumab/farmacologia , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
OBJECTIVE: This study evaluated the potential efficacy of a novel approach to treat COVID-19 patients, using an oxygen-ozone (O2-O3) mixture, via a process called Oxygen-Ozone- Immunoceutical Therapy. The methodology met the criteria of a novel, promising approach to treat successfully elderly COVID-19 patients, particularly when hospitalized in intensive care units (ICUs) Experimental design: We investigated the therapeutic effect of 4 cycles of O2-O3 in 50 hospitalized COVID-19 subjects suffering from acute respiratory disease syndrome (ARDS), aged more than 60 years, all males and undergoing non invasive mechanical ventilation in ICUs. RESULTS: Following O2-O3 treatment a significant improvement in inflammation and oxygenation indexes occurred rapidly and within the first 9 days after the treatment, despite the expected 14-20 days. A significant reduction of inflammatory and thromboembolic markers (CRP, IL-6, D-dimer) was observed. Furthermore, amelioration in the major respiratory indexes, such as respiratory and gas exchange markers (SatO2%, PaO2/FiO2 ratio), was reported. CONCLUSION: Our results show that O2-O3 treatment would be a promising therapy for COVID-19 patients. It leads patients to a fast recovery from ARDS via the improvement of major respiratory indexes and blood gas parameters, following a relatively short time of dispensed forced ventilation (about one to two weeks). This study may encourage the scientific community to further investigate and evaluate the proposed method for the treatment of COVID-19 patients.
Assuntos
Infecções por Coronavirus/terapia , Imunoterapia/métodos , Oxigênio/uso terapêutico , Ozônio/uso terapêutico , Pneumonia Viral/terapia , Síndrome do Desconforto Respiratório/terapia , Idoso , Betacoronavirus , Gasometria , COVID-19 , Infecções por Coronavirus/imunologia , Humanos , Imunoterapia/instrumentação , Infusões Intravenosas , Unidades de Terapia Intensiva , Oxigênio/administração & dosagem , Ozônio/administração & dosagem , Pandemias , Pneumonia Viral/imunologia , Respiração Artificial , Síndrome do Desconforto Respiratório/imunologia , SARS-CoV-2 , Resultado do TratamentoRESUMO
Essa é uma produção do Departamento de Ciência e Tecnologia (Decit) da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE) do Ministério da Saúde (Decit/SCTIE/MS), que tem como missão promover a ciência e tecnologia e o uso de evidências científicas para a tomada de decisão do SUS, tendo como principal atribuição o incentivo ao desenvolvimento de pesquisas em saúde no Brasil, de modo a direcionar os investimentos realizados em pesquisa pelo Governo Federal às necessidades de saúde pública. Informar sobre as principais evidências científicas descritas na literatura internacional sobre tratamento farmacológico para a COVID-19. Além de resumir cada estudo identificado, o informe apresenta também uma avaliação da qualidade metodológica e a quantidade de artigos publicados, de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, entre outros). Foram encontrados 10 artigos e 20 protocolos.
Assuntos
Humanos , Pneumonia Viral/tratamento farmacológico , Infecções por Coronavirus/tratamento farmacológico , Betacoronavirus/efeitos dos fármacos , Cloroquina/uso terapêutico , Interferons/uso terapêutico , Corticosteroides/uso terapêutico , Azitromicina/uso terapêutico , Ritonavir/uso terapêutico , Combinação de Medicamentos , Lopinavir/uso terapêutico , Inibidores de Janus Quinases/uso terapêutico , Hidroxicloroquina/uso terapêutico , Imunoterapia/instrumentação , Medicina Tradicional Chinesa/instrumentaçãoRESUMO
A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.
Assuntos
Vacinas Anticâncer/imunologia , Células Dendríticas/imunologia , Vigilância Imunológica , Imunoterapia/métodos , Neoplasias/terapia , Alitretinoína/farmacologia , Apoptose/efeitos dos fármacos , Apoptose/imunologia , Vacinas Anticâncer/uso terapêutico , Técnicas de Cultura de Células/instrumentação , Técnicas de Cultura de Células/métodos , Linhagem Celular Tumoral , Células Dendríticas/metabolismo , Avaliação Pré-Clínica de Medicamentos/instrumentação , Avaliação Pré-Clínica de Medicamentos/métodos , Citometria de Fluxo/instrumentação , Citometria de Fluxo/métodos , Proteína HMGB1/análise , Proteína HMGB1/imunologia , Proteína HMGB1/metabolismo , Humanos , Imunogenicidade da Vacina , Imunoterapia/instrumentação , Interferon-alfa/farmacologia , Monócitos/imunologia , Monócitos/metabolismo , Neoplasias/imunologia , Neoplasias/patologia , Vacinação/instrumentação , Vacinação/métodosRESUMO
Immune system evasion by cancer cells is one of the hallmarks of cancers, and it occurs with the support of tumor-associated immune cells (TICs) in the tumor microenvironment that increase the growth and invasiveness of tumor cells. With recent advancements in the development of novel near-infrared (NIR)-responsive nanoparticles, specifically eradicating TICs or inducing an inflammatory immune response by activating killer T cells has become possible. This review will discuss the mechanisms and applications of phototriggered immunotherapy in detail. In addition, various nanoparticles employed in phototriggered immunotherapy for cancer treatment will be covered. Furthermore, the challenges and future directions of phototriggered nanoparticle development for anticancer immunotherapy will be briefly discussed.
Assuntos
Imunoterapia/métodos , Nanopartículas/uso terapêutico , Neoplasias/terapia , Fototerapia/métodos , Microambiente Tumoral/imunologia , Animais , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/farmacologia , Humanos , Imunoterapia/instrumentação , Luz , Nanopartículas/química , Neoplasias/imunologia , Neoplasias/patologia , Fotoquimioterapia/instrumentação , Fotoquimioterapia/métodos , Fototerapia/instrumentação , Microambiente Tumoral/efeitos dos fármacosRESUMO
The immunological rehabilitation of the patients with oncological problems after the completion of standard anti-tumour therapy remains a topical problem in modern medicine. The up-to-date phototherapeutic methods find the increasingly wider application for the treatment of such patients including the use of monochromatic visible (VIS) and near infrared (nIR) radiation emitted from lasers and photodiodes. The objective of the present study was to substantiate the expediency of postoperative immune rehabilitation of the patients with breast cancer (BC) by means of irradiation of the body surface with polychromatic visible (pVIS) in combination with polychromatic infrared (pIR) light similar to the natural solar radiation without its minor UV component. The study included 19 patients with stage I--II BC at the mean age of 54.0 +/- 4.28 years having the infiltrative-ductal form of the tumour who had undergone mastectomy. These patients were randomly allocated to two groups, one given the standard course of postoperative rehabilitation (control), the other (study group) additionally treated with pVIS + pIR radiation applied to the lumbar-sacral region from days 1 to 7 after surgery. A Bioptron-2 phototherapeutic device, Switzerland, was used for the purpose (480-3400 nm, 40 mW/cm2, 12 J/cm2, with the light spot diameter of 15 cm). The modern standard immunological methods were employed. It was found that mastectomy induced changes of many characteristics of cellular and humoral immunity; many of them in different patients were oppositely directed. These changes were apparent within the first 7 days postoperatively. The course of phototherapy (PT) was shown to prevent the postoperative decrease in the counts of monocytes and natural killer (NK) cells, the total amount of CD3+ -T-lymphocytes (LPC), CD4+ -T-helpers, activated T-lymphocytes (CD3+ HLA-DR+ cells) and IgA levels as well as intracellular digestion rate of neutrophil-phagocyted bacteria. Moreover PT promoted faster normalization of postoperative leukocytosis and activation of cytotoxic CD8+ -T-LPC, reduced the elevated concentration of immune complexes in blood. Among the six tested cytokines, viz. IL-1beta, TNF-alpha, IL-6, IL-10, IFN-alpha, and IFN-gamma, only the latter two underwent significant elevation of their blood concentrations (IL-6 within 1 day) and IFN-gamma (within 7 days after mastectomy). The course of PT resulted in the decrease of their levels to the initial values. The follow-up of the treated patients during 4 years revealed neither recurrence of the disease nor the appearance of metastases.
Assuntos
Neoplasias da Mama , Imunoterapia , Raios Infravermelhos/uso terapêutico , Fototerapia , Neoplasias da Mama/sangue , Neoplasias da Mama/imunologia , Neoplasias da Mama/reabilitação , Neoplasias da Mama/cirurgia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/metabolismo , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Citocinas/sangue , Citocinas/imunologia , Feminino , Humanos , Imunidade Humoral , Imunoterapia/instrumentação , Imunoterapia/métodos , Ativação Linfocitária , Contagem de Linfócitos , Pessoa de Meia-Idade , Fototerapia/instrumentação , Fototerapia/métodosRESUMO
Background: The most important allergen manufacturers are based in Europe and in the US. In some countries local products are also sold. No comparison between European, US and local products has been made until now. Aim of the study: To determine total protein content and total specific IgE binding capacity or major allergen content of diagnostic extracts from European, US and Mexican origins relative to the CBER/FDA reference extracts for Dermatophagoides pteronyssinus (Dpt), Bermuda grass and cat (10,000 (B) AU/mL). Methods: Diagnostic extracts were purchased from various manufacturers, blinded and shipped to the analysing laboratory, where the following assays were conducted: total protein concentration (Bradford), specific IgE competition ELISA (Dpt and Bermuda grass) and determination of Fel d 1U/mL. When available, CBER/FDA recommended tests and reagents were used. Results: Total protein content of US reference extracts was higher than all other extracts. Relative potency of European and US-bought Dpt extracts 3,3004,400 AU/mL, Bermuda grass 8002,500 BAU/mL and cat 2.14.4 Fel d IU/mL (Ref. 19U/mL), with one exception. Locally produced Mexican products were almost all below 1,000 (B) AU/mL. Conclusions: Three diagnostic extracts from European manufacturers and from Mexican providers which obtain extracts in US have a <50% relative potency compared to 10,000 (B) AU/mL US extracts. Locally produced Mexican extracts have much lower total protein content and specific IgE binding capacity. These in vitro results must be complemented with other in vitro and in vivo skin prick tests to obtain a more complete picture of comparison of potency. Nevertheless results are quite consistent for the allergens tested here
No disponible
Assuntos
/métodos , Alérgenos/uso terapêutico , Dessensibilização Imunológica , Antígenos de Plantas/uso terapêutico , Dermatophagoides pteronyssinus/ultraestrutura , Cynodon/farmacologia , Cynodon/uso terapêutico , Imunoterapia/instrumentação , Imunoterapia/métodos , Dessensibilização Imunológica/métodos , Alérgenos/farmacologia , Alérgenos/farmacocinética , Antígenos de Plantas/farmacologia , México/epidemiologia , Europa (Continente)/epidemiologia , Estados Unidos/epidemiologiaRESUMO
The use of pine nuts, the seeds of Pinus pinea, is on the increasing in the modern Mediterranean diet. Little more than 20 cases of allergy to this tree nut have been published, and cross-reactivity with pine pollen, peanut and almond has already been reported. We describe the case of a young boy with several episodes of anaphylaxis after pine nut ingestion. Specific IgE to pine nut and Artemisia vulgaris was demonstrated by skin prick tests and in vitro determination of specific IgE, although no IgE to pine pollen or other nuts was detected. Immunoblotting of Artemisia vulgaris and pine nut revealed two matching diffuse bands, just below 14 kDa and 30 kDa. The ImmunoCAP® inhibition assays showed complete inhibition of pine nut specific IgE after serum incubation with Artemisia vulgaris extract. As far as we know, this is the first reported case of documented cross-reactivity between pine nut and Artemisia vulgaris
No disponible